Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 19Breast Neoplasms 18Fallopian Tube Neoplasms 13Neoplasm Metastasis 10Triple Negative Breast Neoplasms 8Prostatic Neoplasms 8Neoplasms 7Endometrial Neoplasms 7Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Metastatic Castration-resistant Prostate Cancer 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Solid Tumors 3Neuroendocrine Tumors 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Glioma 3Urinary Bladder Neoplasms 2Sarcoma 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Osteosarcoma 2Neuroblastoma 2Multiple Myeloma 2Medulloblastoma 2Glioblastoma 2Ependymoma 2

Interventions

olaparib 1decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
BRCA1 Mutation × olaparib × 90 days × Clear all
NCT06177171 2026-05-27

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

University of California, San Francisco

Phase 1 Recruiting
18 enrolled

BRCA1 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡